242 related articles for article (PubMed ID: 25605456)
1. Regulatory considerations for companion diagnostic devices.
Lee EY; Shen HC
Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456
[TBL] [Abstract][Full Text] [Related]
2. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
3. Companion diagnostics in oncology - current status and future aspects.
Jørgensen JT
Oncology; 2013; 85(1):59-68. PubMed ID: 23860090
[TBL] [Abstract][Full Text] [Related]
4. Companion diagnostics: the key to personalized medicine. Foreword.
Jørgensen JT
Expert Rev Mol Diagn; 2015 Feb; 15(2):153-6. PubMed ID: 25597758
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the codevelopment of companion diagnostics.
Moore MW; Babu D; Cotter PD
Per Med; 2012 Jul; 9(5):485-496. PubMed ID: 29768776
[TBL] [Abstract][Full Text] [Related]
6. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
7. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
8. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
Pignatti F; Ehmann F; Hemmings R; Jonsson B; Nuebling M; Papaluca-Amati M; Posch M; Rasi G
Clin Cancer Res; 2014 Mar; 20(6):1458-68. PubMed ID: 24634469
[TBL] [Abstract][Full Text] [Related]
9. The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics.
Enzmann H; Meyer R; Broich K
Biomark Med; 2016 Dec; 10(12):1261-1268. PubMed ID: 27661101
[TBL] [Abstract][Full Text] [Related]
10. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
11. [Discussing the usefulness of companion diagnostics - introductory remarks by chairpersons].
Nobori T; Nomura F
Rinsho Byori; 2014 Dec; 62(12):1263-4. PubMed ID: 25823244
[TBL] [Abstract][Full Text] [Related]
12. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
13. [Current issues regarding companion diagnostics and future prospects].
Tazawa Y
Rinsho Byori; 2014 Apr; 62(4):381-9. PubMed ID: 25022068
[TBL] [Abstract][Full Text] [Related]
14. Complementary versus companion diagnostics: apples and oranges?
Milne CP; Bryan C; Garafalo S; McKiernan M
Biomark Med; 2015; 9(1):25-34. PubMed ID: 25605453
[TBL] [Abstract][Full Text] [Related]
15. Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments.
Otsubo Y; Ishiguro A; Uyama Y
Pharmacogenomics; 2013 Jan; 14(2):195-203. PubMed ID: 23327579
[TBL] [Abstract][Full Text] [Related]
16. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
Campbell MR
Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
[TBL] [Abstract][Full Text] [Related]
17. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.
Zaric GS
Pharmacoeconomics; 2016 Jul; 34(7):635-44. PubMed ID: 26899833
[TBL] [Abstract][Full Text] [Related]
18. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
Halim AB
Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
[TBL] [Abstract][Full Text] [Related]
19. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
Jørgensen JT
Trends Cancer; 2016 Dec; 2(12):706-712. PubMed ID: 28741518
[TBL] [Abstract][Full Text] [Related]
20. Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective.
Li Y; Veeraraghavan J; Philip R
Methods Mol Biol; 2020; 2055():701-716. PubMed ID: 31502175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
